CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLAB008

Diagnostic Testing of Iron Homeostasis and Metabolism

Governs reimbursement criteria and coding guidance for laboratory tests assessing iron homeostasis (e.g., serum ferritin, transferrin saturation, hepcidin, GlycA) for BCBSNM members and participating providers.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy CPCPLAB008

Change TypeLiterature/references updatedreimbursement unchanged

Effective DateMar 15, 2024

Next Review Date

Key ActionSubmit accurate documentation and bill using valid HIPAA-approved codes; claims are subject to review and code-edit protocols.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

multipleReimbursable: ferritin

multipleReimbursable: transferrin sat.

1Non-reimbursable: hepcidin

1Non-reimbursable: GlycA

not coveredAsymptomatic screening

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Iron Homeostasis Testing

Iron testing coverage criteria

Covered when ALL of the following apply, except where specific exclusions are listed below:

ALL of the following

Indications for serum ferritin
- For the evaluation of an individual with abnormal hemoglobin and/or hematocrit levels.
- For the evaluation and monitoring of iron overload disorders.
- For individuals with symptoms of hemochromatosis (see Note 1).
- For individuals with first-degree relatives (see Note 2) with confirmed hereditary hemochromatosis (HH).
- For the evaluation of individuals with liver disease.
- For the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease.
- At a frequency of every 1 to 3 months for specified situations.
- In males with secondary hypogonadism.
- For the evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for receiving treatment for anemia.
- For individuals on iron therapy.

ALL of the following

In asymptomatic individuals, the use of ferritin or transferrin measurement, including transferrin saturation, as a screening test is not reimbursable.
Serum hepcidin testing, including immunoassays, is not reimbursable.
The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins is not reimbursable. Please note that carbohydrate-deficient transferrin is out of the scope for this policy.

Billing and plan conflict note

If a conflict arises between this policy and any plan document or provider contract, the plan document or provider contract will govern; providers are responsible for accurate documentation and appropriate use of HIPAA-approved codes and claims are subject to coding and claim-review protocols.

coverage notes

Policy update history and document notes regarding reimbursement and references:

Reimbursement information unchanged in the most recent noted update; document updated with literature review (Policy Update History indicates 'Reimbursement Information unchanged: References revised; some added').

Earlier update on 06/15/2023 states the document was updated with a literature review and that reimbursement information was revised for clarity; references were revised (some added, others removed).

The policy was originally created 11/1/2022 (new policy) and subsequent revisions have focused on literature/reference updates rather than substantive changes to reimbursement criteria.

Procedure Codes and Coding Guidance

Procedure codes guidancemixed

No codes listed

Documentation, Claims, and Authorization Notes

Documentation Required

Documentation, coding, and claims submission

Providers must submit accurate documentation of services performed and bill using valid HIPAA-approved code sets. Claims are subject to code-edit protocols and claim review against plan documents, provider contracts, medical policies, and clinical payment and coding policies.

Use valid code combinations from HIPAA-approved code sets (e.g., AMA CPT, HCPCS, ICD-10-CM/PCS, NDC).
Code claims according to industry-standard coding guidelines (e.g., UB Editor, CMS NCCI/CCI edits, DRG rules).
Be aware claims may be denied or adjusted during claim review and code edit processing if documentation or coding do not support the billed service.

Note

Authorization notes — reimbursement unchanged; literature review updated

The policy notes indicate the document was updated with a literature review while reimbursement information remained unchanged in the most recent update.

Document updated with literature review; references revised or added.

Definitions and Test Examples

First-degree relatives (parents, full siblings, and children)

DefinitionFirst-degree relatives: parents, full siblings, and children of the individual.

ContextUsed in coverage criteria to identify relatives of individuals with confirmed hereditary hemochromatosis (HH) who may be eligible for testing.

NoteSee policy Note 2 for the formal listing of first-degree relatives in reimbursement criteria.

Reimbursable ferritin/transferrin indications; non-reimbursable hepcidin and GlycA for transferrin

Reimbursable — Serum ferritinMeasurement of serum ferritin may be reimbursable for multiple indications (e.g., evaluation of abnormal hemoglobin/hematocrit; evaluation/monitoring of iron overload disorders; symptoms of hemochromatosis; first-degree relatives of confirmed HH; liver disease; HLH and Still Disease; specified frequencies; males with secondary hypogonadism; CKD patients receiving/considered for anemia treatment; individuals on iron therapy).

Policy Revision History

TBDliterature_update

Document updated with literature review; reimbursement information unchanged; references revised and some added.

2023-06-15literature_and_clarity_update

Document updated with literature review and reimbursement information revised for clarity; references revised with additions and removals.

2022-11-01policy_creationLatest

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy CPCPLAB008

Change TypeLiterature/references updatedreimbursement unchanged

Effective DateMar 15, 2024

Next Review Date

Key ActionSubmit accurate documentation and bill using valid HIPAA-approved codes; claims are subject to review and code-edit protocols.

SourceLink

On This Page

Reimbursement information reported as unchanged in the latest noted update (TBD entry and 06/15/2023 note).

Reimbursable — Transferrin saturationMeasurement of transferrin saturation (using serum iron and serum iron binding capacity) may be reimbursable for evaluation of iron overload (including individuals with symptoms of hemochromatosis or first-degree relatives with confirmed HH) and for evaluation of iron deficiency anemia.

Not reimbursable — Serum hepcidinSerum hepcidin testing, including immunoassays, is not reimbursable.

Not reimbursable — GlycA for transferrin/glycoproteinsThe use of GlycA testing to measure or monitor transferrin or other glycosylated proteins is not reimbursable.

Scope noteCarbohydrate‑deficient transferrin is out of scope for this policy.

Iron-related biomarkers context — cited references

GlycA evidenceGlycA is cited as a biomarker associated with chronic inflammation and long-term risk of severe infection (Ritchie et al., 2015); this underpins the policy exclusion of GlycA for measuring transferrin/glycoproteins.

Transferrin receptor 2 literatureFunctional roles and therapeutic value of transferrin receptor 2 are documented (Roetto et al., 2018), providing context for transferrin-related testing considerations.

Ferritin, hepcidin, and inflammationImpact of inflammation on ferritin and hepcidin and implications for managing iron deficiency anemia are described (Ueda & Takasawa, 2018; Suchdev et al., 2017), informing interpretation of iron biomarkers in inflammatory states.

Hereditary hemochromatosis and iron overloadMolecular diagnostics and management of hereditary hemochromatosis and guidelines for quantifying iron overload are referenced (Santos et al., 2012; van Bokhoven et al., 2011; Wood, 2014), supporting criteria for ferritin and transferrin saturation testing.